Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
$0.00
$0.05
$1.97
$25.24M-0.0618,253 shs6,100 shs
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
$1.16
-0.9%
$21.77
$0.51
$10.55
$8.61M0.933.15 million shs268,123 shs
Acerus Pharmaceuticals Co. stock logo
ASPCF
Acerus Pharmaceuticals
$0.22
$0.22
$0.22
$8.16
$1.70M0.691,500 shsN/A
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
$0.48
$0.31
$10.10
$6.88M4.16713,628 shsN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
$0.22
$0.22
$0.08
$0.34
$56.90M2.65,474 shsN/A
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
0.00%0.00%0.00%0.00%0.00%
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
+0.86%+1.74%-11.36%+24.47%+14.71%
Acerus Pharmaceuticals Co. stock logo
ASPCF
Acerus Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
0.00%0.00%0.00%0.00%0.00%
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
ASPCF
Acerus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
0.00
N/AN/AN/A
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
0.00
N/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
ASPCF
Acerus Pharmaceuticals
0.00
N/AN/AN/A
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
0.00
N/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
$20K0.00N/AN/A($0.03) per share0.00
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
N/AN/AN/AN/A$2.01 per shareN/A
Acerus Pharmaceuticals Co. stock logo
ASPCF
Acerus Pharmaceuticals
$2.12M0.80N/AN/A($3.38) per share-0.07
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
$96.43M0.00N/AN/A$16.96 per share0.00
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
$7.38M7.71N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
-$1.45MN/A0.00N/AN/A-41,453.98%N/A-574.29%N/A
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
-$27.12M-$3.467.73N/AN/AN/A36.08%27.40%N/A
Acerus Pharmaceuticals Co. stock logo
ASPCF
Acerus Pharmaceuticals
-$33.82M-$3.57N/AN/A-924.33%N/A-74.62%N/A
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
-$157.19M-$17.72N/AN/AN/A-393.39%-101.29%-28.68%N/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
-$18.79M-$0.08N/AN/A-254.66%-346.72%-94.54%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
N/AN/AN/AN/AN/A
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
N/AN/AN/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
ASPCF
Acerus Pharmaceuticals
N/AN/AN/AN/AN/A
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
N/AN/AN/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
N/A
0.03
0.07
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
N/A
3.25
3.25
Acerus Pharmaceuticals Co. stock logo
ASPCF
Acerus Pharmaceuticals
N/A
0.67
0.34
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
1.11
1.03
0.72
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
0.64
1.35
0.90
CompanyEmployeesShares OutstandingFree FloatOptionable
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
242.07 millionN/ANot Optionable
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
167.42 millionN/ANot Optionable
Acerus Pharmaceuticals Co. stock logo
ASPCF
Acerus Pharmaceuticals
147.71 millionN/ANot Optionable
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
29013.75 millionN/AOptionable
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
29258.62 millionN/ANot Optionable

Recent News About These Companies

Takeda Pharmaceutical Co. Ltd. ADR
Other OTC Pharmaceuticals - Lithuania
Acerus Reports Second Quarter 2022 Financial Results

Media Sentiment Over Time

Amarillo Biosciences stock logo

Amarillo Biosciences OTCMKTS:AMAR

Amarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.

Anchiano Therapeutics stock logo

Anchiano Therapeutics NASDAQ:ANCN

Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.

Acerus Pharmaceuticals stock logo

Acerus Pharmaceuticals OTCMKTS:ASPCF

$0.22 0.00 (0.00%)
As of 07/21/2023

Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men's health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.

Melinta Therapeutics stock logo

Melinta Therapeutics NASDAQ:MLNT

Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is headquartered in New Haven, Connecticut.

Acerus Pharmaceuticals stock logo

Acerus Pharmaceuticals OTCMKTS:TRLPF

$0.22 0.00 (0.00%)
As of 07/21/2023

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.